Pharmacally
Disease & Drugs
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Disease & Drugs
New Drug ApprovalAstraZeneca Wins FDA Approval for Imfinzi in Bladder CancerThe FDA has approved AstraZeneca’s perioperative Imfinzi plus enfortumab vedotin regimen for adults with cisplatin-ineligible muscle-invasive bladder cancer.Fact-Checked
New Drug ApprovalRoche’s Obinutuzumab Wins First FDA Approval in Membranous NephropathyThe FDA has approved obinutuzumab (Gazyva) as the first specifically approved treatment for adults with primary membranous nephropathy at risk of disease progression.Fact-Checked
Clinical TrialsRoche Secures Positive CHMP Recommendation for Obinutuzumab in SLERoche’s obinutuzumab has received a positive CHMP recommendation for systemic lupus erythematosus in the EU. The recommendation follows Phase III ALLEGORY results showing improved disease activity, sustained glucocorticoid…Fact-Checked
Clinical TrialsMerck Gains EU CHMP Backing for Belzutifan in Advanced RCCMerck’s belzutifan plus lenvatinib combination receives a positive EU CHMP opinion for previously treated advanced clear-cell renal cell carcinoma.Fact-Checked
Clinical TrialsZai Lab’s ZL-1503 Sustains Atopic Dermatitis Biomarker Suppression Through Week 12Zai Lab’s investigational bispecific antibody ZL-1503 demonstrated sustained IL-13 pathway biomarker suppression through Week 12 following a single intravenous dose.Fact-Checked
Clinical TrialsBioCryst Reports Reduced Healthcare Utilization Across ORLADEYO StudiesBioCryst reported real-world evidence showing a 30% reduction in overall angioedema-related medical visits per patient-year among 78 patients with hereditary angioedema who switched to ORLADEYO (berotralstat).Fact-Checked
Clinical TrialsOrganon Reports Consistent Skin and Itch Improvements With VTAMAOrganon reported pooled post-hoc findings from the Phase 3 ADORING 1 and ADORING 2 trials showing consistent VTAMA (tapinarof) cream responses across atopic dermatitis subgroups.Fact-Checked
Clinical TrialsRegeneron’s Baloncibart Delivers Sustained Heart Rate Benefits in POTSRegeneron’s investigational NPR1-blocking antibody baloncibart reduced orthostatic heart rate response through Day 29 in the Phase 2 PINNACLE trial.Fact-Checked
Clinical TrialsIonis Reports Long-Term Attack Reduction with DAWNZERA in HAEIonis Pharmaceuticals reported two-year OASISplus results showing a 95% reduction in hereditary angioedema attack rates with DAWNZERA in the open-label extension cohort.Fact-Checked
Clinical TrialsPharvaris Adds Long-Term HAE Prophylaxis and On-Demand Data for DeucrictibantPharvaris presented additional clinical findings for deucrictibant, including sustained HAE attack reduction over nearly 34 months in the CHAPTER-1 extension, improved quality-of-life outcomes and durable responses following on-demand…Fact-Checked
Clinical TrialsCuraSen’s CuraAX Improves Standing Blood Pressure in Phase 2aCuraSen Therapeutics reports statistically significant, dose-dependent improvements in standing systolic blood pressure with CuraAX (CST-3056) in a 12-patient Phase 2a study of neurogenic orthostatic hypotension.Fact-Checked
Clinical TrialsLilly’s Taltz-Zepbound Combination Delivers 43.7% ACR50 ResponseEli Lilly’s Phase 3b TOGETHER-PsA trial showed that combining Taltz (ixekizumab) with Zepbound (tirzepatide) improved psoriatic arthritis outcomes and weight reduction at Week 52 compared with Taltz alone.…Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.